Hodgkin Lymphoma, Version 2.2015
Richard T. Hoppe(Stanford Medicine), Hema Sundar(National Comprehensive Cancer Network), Joachim Yahalom(Unknown), Bouthaina S. Dabaja, Leo I. Gordon(Northwestern University), David G. Maloney(Fred Hutch Cancer Center), Monika L. Metzger(St. Jude Children's Research Hospital), Matthew M. Poppe(University of Utah), Peter Mauch(Western Sydney University), Jennifer L. Burns(National Comprehensive Cancer Network), Rachel Rabinovitch(University of Colorado Boulder), Ephraim P. Hochberg(Massachusetts General Hospital), Andres Forero(University of Alabama at Birmingham), Weiyun Z. Ai(City College of San Francisco), Kristie A. Blum(Emory University), Ranjana H. Advani(Stanford Medicine), David Morgan(Vanderbilt University Medical Center), Christina Tsien(McGill University Health Centre), Francisco J. Hernandez‐Ilizaliturri(Roswell Park Comprehensive Cancer Center), Richard F. Ambinder(Johns Hopkins University), Carolyn Mulroney(University of California San Diego Medical Center), Patricia Aoun(University of Nebraska Medical Center), Nadia Khan(Fox Chase Cancer Center), Patrick B. Johnston(Mayo Clinic in Arizona), Cecil M. Benitez(Cancer Institute (WIA)), Robert Chen(AstraZeneca (United States)), Jiayi Huang(Chongqing Medical University), Joseph O. Moore(Cancer Institute (WIA)), Philip J. Bierman(Susan Thompson Buffett Foundation), Stuart Seropian(Yale Cancer Center), Craig H. Moskowitz(University of Miami), Celeste Bello(Moffitt Cancer Center), Jane N. Winter(Northwestern University)
Cited by 53
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k